Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inotek Pharmaceuticals, a clinical-stage, drug-development company, has announced that the US Patent and Trademark Office has issued two new patents covering the company's two lead clinical compounds INO-8875 and INO-4885.
Subscribe to our email newsletter
INO-8875 is a selective adenosine 1 agonist in Phase I clinical development as a topical agent for the treatment of elevated intraocular pressure associated with primary open angle glaucoma and ocular hypertension.
INO-4885 is a peroxynitrite decomposition catalyst in Phase I clinical development for the prevention of contrast-induced nephropathy in patients undergoing procedures involving contrast imaging agents who are at high risk of kidney damage.
Paul Howes, president and CEO of Inotek, said: “These patents cover important technology discovered and developed by Inotek scientists and serve as an initial foundation for our growing pipeline in ophthalmology and other select indications with significant unmet medical need.”